Edition:
India

Pharma Mar SA (PHMR.MC)

PHMR.MC on Madrid SE C.A.T.S.

1.64EUR
9:05pm IST
Change (% chg)

€-0.01 (-0.90%)
Prev Close
€1.66
Open
€1.66
Day's High
€1.66
Day's Low
€1.62
Volume
426,002
Avg. Vol
557,450
52-wk High
€4.06
52-wk Low
€1.40

Select another date:

Wed, Feb 28 2018

BRIEF-Pharma Mar FY Net Loss Widens To 26.7 Mln Euros YoY

* FY NET LOSS 26.7 MILLION EUROS VERSUS LOSS 24.1 MILLION EUROS YEAR AGO

BRIEF-Pharma Mar Announces Positive Results Of Its MI13004 Antibody Conjugate

* ANNOUNCES POSITIVE RESULTS OF ITS ANTIBODY CONJUGATE ACTIVE IN BREAST, OVARIAN AND GASTRIC CANCERS Source text for Eikon:

BRIEF-Pharma Mar Licenses Marine-Derived Payloads To Seattle Genetics

* LICENSES FULLY SYNTHETIC MARINE-DERIVED PAYLOADS TO SEATTLE GENETICS FOR USE IN DRUG CONJUGATES

BRIEF-Pharma Mar Says Phase III Trial With Zepsyre In Resistant Ovarian Cancer Not Met Its Primary Endpoint

* CORAIL PHASE III WITH ZEPSYRE IN RESISTANT OVARIAN CANCER HAS NOT MET ITS PRIMARY ENDPOINT Source text for Eikon:

BRIEF-Pharma Mar Requests Re-Examination Process For Aplidin From EMA

* REQUESTS PROCESS OF RE-EXAMINATION FOR APLIDIN FROM THE EUROPEAN MEDICINES AGENCY (EMA)

BRIEF-Pharma Mar Signs Distribution License Agreement For Aplidin In Israel

* SIGNS COMMERCIALIZATION AND DISTRIBUTION LICENSE AGREEMENT FOR APLIDIN WITH MEGAPHARM IN ISRAEL Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Select another date: